Search results for "ORAL ANTICOAGULANT"

showing 10 items of 31 documents

Use of oral anticoagulant drugs in older patients with atrial fibrillation in internal medicine wards

2018

no abstract available

MaleAdministration Oral030204 cardiovascular system & hematologyBody Mass IndexOral anticoagulant drug0302 clinical medicineElderlyDrug PrescriptionOlder patientsRetrospective Studie80 and overMedicine030212 general & internal medicineStrokeRandomized Controlled Trials as TopicAged 80 and overAtrial fibrillation; Elderly; Oral anticoagulant drugs; Prescription rate; Internal MedicineAtrial fibrillationStrokeObservational Studies as TopicAtrial fibrillation Elderly Oral anticoagulant drugs Prescription rate Internal MedicineAdministrationOral anticoagulantFemaleHumanOralmedicine.medical_specialtyOral anticoagulant drugsSocio-culturaleDrug Prescriptions03 medical and health sciencesInternal medicineInternal MedicineHumansPrescription rateAgedRetrospective Studiesbusiness.industrySettore MED/09 - MEDICINA INTERNAAnticoagulantAnticoagulantsRetrospective cohort studymedicine.diseaseAtrial fibrillationAtrial fibrillation; Elderly; Oral anticoagulant drugs; Prescription rate; Administration Oral; Aged; Aged 80 and over; Anticoagulants; Atrial Fibrillation; Body Mass Index; Drug Prescriptions; Female; Humans; Internal Medicine; Male; Observational Studies as Topic; Randomized Controlled Trials as Topic; Retrospective Studies; Stroke; Internal MedicineObservational Studies as TopicbusinessBody mass indexAtrial fibrillation Elderly Oral anticoagulant drugs Prescription rate
researchProduct

Recanalization Therapies in Acute Ischemic Stroke Patients Impact of Prior Treatment With Novel Oral Anticoagulants on Bleeding Complications and Out…

2015

Background— We explored the safety of intravenous thrombolysis (IVT) or intra-arterial treatment (IAT) in patients with ischemic stroke on non-vitamin K antagonist oral anticoagulants (NOACs, last intake <48 hours) in comparison with patients (1) taking vitamin K antagonists (VKAs) or (2) without previous anticoagulation (no-OAC). Methods and Results— This is a multicenter cohort pilot study. Primary outcome measures were (1) occurrence of intracranial hemorrhage (ICH) in 3 categories: any ICH (ICH any ), symptomatic ICH according to the criteria of the European Cooperative Acute Stroke Study II (ECASS-II) (sICH ECASS-II ) and the National Institute of Neurological Disorders and Stroke …

MaleBrain Ischemia/blood/drug therapyVitamin Kmedicine.medical_treatmentendovascular proceduresAnticoagulants/administration & dosage/adverse effects/classification/therapeutic useAdministration OralPilot ProjectsTissue plasminogen activatorBrain IschemiaCohort Studies2737 Physiology (medical)Atrial Fibrillation80 and overThrombolytic TherapyVitamin K/antagonists & inhibitorsStrokethrombolytic therapyAged 80 and overIncidenceAtrial fibrillationThrombolysisMiddle Aged3. Good healthvitamin K antagonistsTreatment OutcomeAdministrationAcute DiseaseCohortCerebral Hemorrhage/chemically induced/epidemiologyFemaleCardiology and Cardiovascular MedicineAtrial Fibrillation/complicationsmedicine.drugOralmedicine.medical_specialtyanticoagulantsnon-vitamin K antagonist oral anticoagulantsFactor Xa Inhibitors/administration & dosage/adverse effects/therapeutic useintracranial hemorrhagesintra-arterial treatment610 Medicine & healthAntithrombins2705 Cardiology and Cardiovascular MedicineDabigatranFibrinolytic AgentsPhysiology (medical)Internal medicinemedicineischemic strokeHumansAgedCerebral HemorrhageIntracerebral hemorrhageFibrinolytic Agents/therapeutic usebusiness.industryAntithrombins/administration & dosage/adverse effects/therapeutic usemedicine.diseaseddc:616.810040 Clinic for Neurologyanticoagulants; endovascular procedures; intra-arterial treatment; intracranial hemorrhages; ischemic stroke; non-vitamin K antagonist oral anticoagulants; thrombolytic therapy; vitamin K antagonistsPropensity score matchingbusinessFactor Xa InhibitorsCirculation
researchProduct

Appropriateness of oral anticoagulant therapy prescription and its associated factors in hospitalized older people with atrial fibrillation

2018

Aims: Although oral anticoagulants (OACs) are effective in preventing stroke in older people with atrial fibrillation (AF), they are often underused in this particularly high-risk population. The aim of the present study was to assess the appropriateness of OAC prescription and its associated factors in hospitalized patients aged 65 years or older. Methods: Data were obtained from the retrospective phase of Simulation-based Technologies to Improve the Appropriate Use of Oral Anticoagulants in Hospitalized Elderly Patients With Atrial Fibrillation (SIM-AF) study, held in 32 Italian internal medicine and geriatric wards. The appropriateness of OAC prescription was assessed, grouping patients …

MaleOralappropriateness of prescriptionappropriateness of prescription atrial fibrillation internal medicine geriatric wards older patients oral anticoagulantSocio-culturaleAdministration OralHemorrhageInappropriate PrescribingDrug Prescriptionsinternal medicine and geriatric wardDose-Response Relationshipolder patientRisk Factorsoral anticoagulant80 and overHumansatrial fibrillationPharmacology (medical)Prospective StudiesAgedRetrospective StudiesAged 80 and overPharmacologygeriatric wardsDose-Response Relationship DrugSettore MED/09 - MEDICINA INTERNAAge FactorsAnticoagulantsinternal medicine and geriatric wardsOriginal Articlesolder patientsappropriateness of prescription; atrial fibrillation; internal medicine and geriatric wards; older patients; oral anticoagulant;appropriateness of prescription; atrial fibrillation; internal medicine and geriatric wards; older patients; oral anticoagulant; Pharmacology; Pharmacology (medical)Strokeinternal medicineappropriateness of prescription; atrial fibrillation; internal medicine and geriatric wards; older patients; oral anticoagulantAdministrationFemaleDrug
researchProduct

Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.

2015

Introduction: Atrial fibrillation (AF) is associated with an increased risk of thromboembolic events. Many patients with AF receive chronic anticoagulation, either with vitamin K antagonists (VKAs) or with non-VKA oral anticoagulants (NOACs). We sought to analyze variables associated with prescription of NOAC. Methods: Patients with AF under anticoagulation treatment were prospectively recruited in this observational registry. The sample comprised 1290 patients under chronic anticoagulation for AF, 994 received VKA (77.1%) and 296 NOAC (22.9%). Univariate and multivariate analyses were performed to identify variables associated with use of NOAC. Results: Mean age was 73.8 ± 9.4 years, and 4…

MaleVitamin KClinical Decision-MakingMEDLINEAdministration OralHemorrhage030204 cardiovascular system & hematologyVitamin kanticoagulant treatment03 medical and health sciences0302 clinical medicineClinical decision makingFibrinolytic AgentsAtrial FibrillationmedicineHumansPharmacology (medical)030212 general & internal medicineAgedPharmacologyAged 80 and overbusiness.industrynonvitamin K antagonist oral anticoagulantsAnticoagulantsAtrial fibrillationMiddle Agedmedicine.diseasevitamin K antagonistsIncreased riskAnticoagulant therapyAnesthesiaOral anticoagulantFemaleCardiology and Cardiovascular Medicinebusiness
researchProduct

Perioperative risk of bleeding with antithrombotic agents in macular surgery: a national, prospective, multicentre study

2020

International audience; Purpose To compare the risk of haemorrhagic complications in elective macular surgery between patients with no antithrombotic (AT) treatment (defined as patients with no history of AT therapy or who discontinued AT therapy) and patients who continued AT treatment during the surgery. Methods E-case report forms were prospectively recorded in a database before vitreoretinal surgery and 1 month after. Data on patient characteristics, surgical techniques, haemorrhagic complications and antithrombotic status were collected. Patients with retinal detachment, proliferative diabetic retinopathy and previous retinal haemorrhage were excluded. Results A total of 748 procedures…

Male[SDV]Life Sciences [q-bio]030204 cardiovascular system & hematologynoncardiac surgeryantiplateletsurgery0302 clinical medicineRisk FactorsAntithromboticMedicineProspective Studiesoral anticoagulantsguidelinesantithrombotic agenteducation.field_of_studyAnticoagulantvitreoretinalRetinal HemorrhageGeneral MedicineDiabetic retinopathy3. Good healthPopulation SurveillanceFemalemacular surgeryhaemorrhagehemorrhagemanagementmedicine.medical_specialtymedicine.drug_classPopulationPostoperative Hemorrhagemaintenance03 medical and health sciencesHumans[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrganseducationAgedbusiness.industryanticoagulantAnticoagulantsPerioperativeOdds ratioRetinal Perforationsmedicine.diseasedual antiplatelet therapyvitreoretinal surgeryConfidence intervalSurgerywarfarinOphthalmology030221 ophthalmology & optometrybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up StudiesRetinal haemorrhage
researchProduct

Rivaroxaban-induced hepatotoxicity

2017

Aim/Objective/Background Direct-acting oral anticoagulant drugs are marketed worldwide for the primary and secondary prevention and treatment of thromboembolic disorders. Rivaroxaban, an oral, direct factor Xa inhibitor, is one of the most used. Rivaroxaban-induced hepatotoxicity is unusual, although a number of adverse reports have recently been reported. Here, we report two new cases of rivaroxaban-induced hepatitis. Methods A systematic search of case reports on the MEDLINE database encompassing the years 2008–2016 was carried out.Additional references were obtained following a manual search of the retrieved papers. We report two new cases of adverse events occurred in patients treated w…

Malemedicine.medical_specialtySettore MED/09 - Medicina Internamedicine.drug_mechanism_of_actionFactor Xa InhibitorMEDLINE030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRivaroxabanInternal medicinemedicineHumansAgedAged 80 and overSecondary preventionRivaroxabanHepatologybusiness.industryGastroenterologydrug-induced liver injury hepatotoxicity pharmacovigilancerivaroxabanOral anticoagulantFemale030211 gastroenterology & hepatologyChemical and Drug Induced Liver InjurybusinessFactor Xa Inhibitorsmedicine.drugEuropean Journal of Gastroenterology & Hepatology
researchProduct

Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10

2009

SummaryUnanticipated elevation of the INR is common in patients receiving warfarin. We performed a prospective cohort study of 107 warfarintreated patients with INR values of more than 10 who received a single 2.5 mg dose of oral vitamin K. During the first week, one patient experienced major bleeding, and one died. In the first 90 days after enrolment four patients had major bleeding (3.7%, 1.0% to 9.3%), eight patients (7.5%, 3.3% to 14.2%) died and two had objectively confirmed thromboembolism. Based on our low rate of observed major bleeding we conclude that 2.5 mg of oral vitamin K is a reasonable treatment for patients with INR values of more than 10 who are not actively bleeding.

Malemedicine.medical_specialtyVitamin Kmedicine.drug_classAdministration OralHemorrhagePharmacotherapyInternal medicinemedicineCoagulopathyHumansInternational Normalized RatioProspective StudiesProspective cohort studyAgedAged 80 and overVenous ThrombosisVascular diseasebusiness.industryAnticoagulantWarfarinAnticoagulantsHematologyMiddle Agedmedicine.diseaseThrombosisSurgeryFemaleINR oral anticoagulantsWarfarinbusinessFollow-Up Studiesmedicine.drugCohort studyThrombosis and Haemostasis
researchProduct

Non-valvular Atrial Fibrillation in CKD: Role of Vitamin K Antagonists and Direct Oral Anticoagulants. A Narrative Review

2021

Atrial fibrillation (AF) is the most common arrhythmia in chronic kidney disease (CKD), with a close bidirectional relationship between the two entities. The presence of CKD in AF increases the risk of thromboembolic events, mortality and bleeding. Vitamin K antagonists (VKA) have been the mainstay of treatment for the prevention of thromboembolic events in AF until recently, with confirmed benefits in AF patients with stage 3 CKD. However, the risk-benefit profile of VKA in patients with AF and stages 4–5 CKD is controversial due to the lack of evidence from randomized controlled trials. Treatment with VKA in CKD patients has been associated with conditions such as poorer anticoagulation q…

Medicine (General)medicine.medical_specialtyVitamin KMini ReviewLower riskurologic and male genital diseaseslaw.inventionDirect oral anticoagulantsR5-920Randomized controlled triallawInternal medicineFibril·lació auricularMalalties cròniquesMedicineatrial fibrillationStrokeCalciphylaxisKidney diseasesbusiness.industryWarfarinAcute kidney injuryanticoagulant-related nephropathyAtrial fibrillationGeneral Medicinemedicine.diseaseVitamines KAtrial fibrillationfemale genital diseases and pregnancy complicationsVitamin K antagonistsArítmiaChronic diseasesInsuficiència renal crònicaAnticoagulants (Medicina)CardiologyMalalties del ronyóMedicineAnticoagulants (Medicine)businesschronic kidney diseasemedicine.drugKidney diseaseFrontiers in Medicine
researchProduct

Management of Direct Oral Anticoagulants in Patients with Atrial Fibrillation Undergoing Cardioversion

2019

Atrial fibrillation the most common cardiac arrhythmia. Its incidence rises steadily with each decade, becoming a real “epidemic phenomenon”. Cardioversion is defined as a rhythm control strategy which, if successful, restores normal sinus rhythm. This, whether obtained with synchronized shock or with drugs, involves a periprocedural risk of stroke and systemic embolism which is reduced by adequate anticoagulant therapy in the weeks before or by the exclusion of left atrial thrombi. Direct oral anticoagulants are safe, manageable, and provide rapid onset of oral anticoagulation; they are an important alternative to heparin/warfarin from all points of view, with a considerable reduction in b…

Medicine (General)medicine.medical_specialtymedicine.medical_treatmentElectric CountershockAdministration OralReviewCardioversionDrug Administration ScheduleR5-920Quality of lifeInternal medicineAtrial FibrillationmedicineHumanscardiovascular diseaseselectrical cardioversion (ec)Strokedirect oral anticoagulants (doacs)business.industryWarfarinAnticoagulantsCardiac arrhythmiaAtrial fibrillationGeneral MedicineHeparinmedicine.diseaseatrial fibrillation (af)Shock (circulatory)cardiovascular systemCardiologymedicine.symptombusinessmedicine.drugMedicina
researchProduct

Optimal duration of treatment in surgical patients with calf venous thrombosis localized only in one or two leg.

2006

OBJECTIVE: This retrospective study was planned for a good risk assessment of asymptomatic patients affected by ventricular pre-excitation. METHODS: From 1985 to 2007, 124 patients with an atrioventricular pathway (electrocardiographic signs of ventricular pre-excitation) were admitted to our cardiology division. The average age was 7 years (range 1 month to 18 years). The mean follow-up period in the whole population of patients was 4.2 years (range 1-13 years). Four patients were lost during the follow-up. During this period, all patients remained in good health. In all of them, we performed a Holter evaluation every year. An intermittent pathway was detected in 18 patients (15%), and fou…

ORAL ANTICOAGULANT-THERAPYACUTE PULMONARY-EMBOLISM
researchProduct